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Backgrounds: Fibrotic nonspecific interstitial pneumonia (f-NSIP) has been recognized as
a distinct disease entity. KL-6 has been reported to be a useful serum marker in interstitial lung
diseases. However, few previous reports evaluated the value of serum KL-6 exclusively in
f-NSIP, as distinct from other subtypes of idiopathic interstitial pneumonia, therefore the asso-
ciations of serum KL-6 with clinical and radiologic findings in this population remain unclear.
Methods: Serum KL-6 levels were measured in twenty-six consecutive patients with f-NSIP
diagnosed by surgical lung biopsy. Pulmonary function testing, bronchoalveolar lavage, subjec-
tive measurement of dyspnea using baseline dyspnea index (BDI), and HRCTwere performed in
parallel. Two radiologists conducted independent visual examinations of the pattern and
extent of abnormalities on HRCT.
Results: Serum KL-6 levels were elevated above the cut-off level in all patients. In univariate
analysis serum KL-6 levels showed negative correlations with BDI (rhoZ 0.52; p< 0.01).
Serum KL-6 had positive correlations with the extent of several patterns of opacities
(rhoZ 0.56e0.62; p< 0.01). Among them, only the extent of traction bronchiectasis in HRCT
showed significant association with serum KL-6 in multivariate analysis (b-coefficientZ 0.043;
p< 0.01).supported by a grant-in-aid for interstitial lung diseases from the Japanese Ministry of Health and
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128 K. Sakamoto et al.Conclusions: Serum levels of KL-6 were elevated in f-NSIP, and were correlated with the extent
of fibrotic abnormalities on HRCT, suggesting a value of serum KL-6 as a marker for fibrosis in
f-NSIP.
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Fibrotic nonspecific interstitial pneumonia (f-NSIP) has
been recognized as one of the major types of chronic
idiopathic interstitial pneumonia, along with usual inter-
stitial pneumonia/idiopathic pulmonary fibrosis (IPF).1e3
Recently, f-NSIP has become recognized as a distinct
disease entity with characteristic clinical, radiologic, and
pathologic features that differ from other idiopathic
interstitial pneumonias.3 However, long-term prognosis and
optimal therapeutic strategy remains largely unclear.
Hence, the identification of useful biomarkers for f-NSIP is
anticipated.
KL-6, one of potent candidates of serum markers for
idiopathic interstitial pneumonias, is a high molecular
weight, mucin-like glycoprotein classified as human MUC1
mucin. KL-6 was strongly expressed by atypical and/or
regenerating type II pneumocytes in tissue sections from
patients with interstitial lung diseases.4 Serum levels of KL-6
have been reported to be elevated in various interstitial lung
diseases such as idiopathic pulmonary fibrosis, collagen
vascular disease associated interstitial pneumonias, and
other interstitial lung disorders.5e9
Several reports have reported the role of KL-6 in patients
with idiopathic interstitial pneumonias (IIPs),10,11 Little
study has, however, evaluated the value of serum KL-6
exclusively in patients with f-NSIP, distinct from other
subtypes of IIPs. Moreover multidimensional evaluation
including serum marker, clinical symptom, pulmonary
function, bronchoalveolar lavage and high resolution CT
findings is scarce in this population.
To assess whether serum KL-6 reflects clinical and
radiological findings and is valid for serum marker in
patients with f-NSIP, we hereby conducted a comprehen-
sive study on the correlations between serum levels of KL-6
and other disease parameters including pulmonary func-
tion, severity of dyspnea, BAL findings, and high resolution
CT findings in patients with idiopathic f-NSIP, the diagnosis
of which was confirmed by surgical lung biopsy.
Materials and methods
Study subjects
The study was approved by the Ethics Committee of Tosei
General Hospital. Consecutive patients with idiopathic
nonspecific interstitial pneumonia diagnosed at Tosei
General Hospital between April 2000 and March 2007 were
retrospectively reviewed. All patients underwent surgical
lung biopsy (SLB), and the diagnosis of f-NSIP was confirmed
by two lung pathologists. Patients with clinically evident
collagen vascular diseases were excluded. No patients had
received medical treatment such as corticosteroid and
immunosuppressants prior to SLB.Shortly before the SLB, all patients underwent the
following evaluations: (1) measurement of serum levels of
KL-6, LDH, and C reactive protein (CRP); (2) arterial blood
gas analysis while breathing room air; (3) pulmonary func-
tion testing; (4) bronchoalveolar lavage; (5) subjective
measurement of dyspnea with baseline dyspnea index
(BDI)(14); and (6) high resolution CT. Measurements of
serum KL-6 were performed using an electro-
chemiluminescence immunoassay kit (Sanko Junyaku;
Kobe, Japan; reference range <500 U/mL) following the
instructions of the manufacturer. Serum LDH and CRP levels
were measured using commercially available kits (for LDH:
Sika-liquid LDH-J, Kantoh Kagaku, Tokyo, Japan, reference
range 119-229 U/L; for CRP: Iatro-CRP, Mitsubishi Chemical
Medience, Tokyo, reference range <0.301 mg/dL). We
adopted the upper limits of the reference levels as the cut-
off points in order to assess the diagnostic sensitivities of
KL-6, LDH, and CRP.
Analysis of high resolution CT findings
CT scans were obtained with 2 mm collimation at 10e
15 mm intervals through the chest. The images were
reconstructed using a high spatial frequency algorithm. Two
radiologists independently interpreted patterns and
extents of pulmonary parenchymal abnormalities on CT
scans. They were blind to patients’ information including
serum concentration of KL-6. The patterns of parenchymal
abnormalities were subcategorized into areas of ground-
glass opacity, air-space consolidation, irregular linear
opacity, and honeycombing. Presence of traction bronchi-
ectasis was also assessed. Extents of abnormalities were
semi-quantitatively scored according to a previous report.12
The images were visually assessed at the following five
levels: aortic arch, azygos arch, distal portion of the
bronchus intermedius, right inferior pulmonary vein, and
liver dome. The extent of each pattern of parenchymal
abnormality was scored to the nearest 5% level. The overall
extent of lung involvement was calculated by combining
the figures of visual estimation at each level with correc-
tion factors of 1.1, 1.2, 1.4, 1.3, and 1.0 at each corre-
sponding level for lung volume. We also defined the extent
of traction bronchiectasis as the number of lung segments
which were involved with traction bronchiestasis. Averaged
scores of the two observers were used for the statistical
analysis.
Statistical analysis
Binomial exact 95% confidence intervals (CIs) were calcu-
lated for the sensitivities of serum markers. The correla-
tions between serum KL-6 and continuous variables were
assessed using Pearson’s correlation analysis. As the
distribution of serum KL-6 levels was not normal, a natural
logarithmic transformation was made to achieve normality.
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ordered scales such as BDI was assessed using Spearman’s
nonparametric analysis. The correlation between serum KL-
6 levels and the extent of abnormal parenchymal opacities
was also assessed using Spearman’s nonparametric analysis,
since it was impossible to achieve normal distribution by
log-transformation for them. Weighted kappa statistic was
used to assess interobserver agreement in high-resolution
CT findings.13
As for the extents of HRCT abnormalities, multivariate
linear regression analysis was also performed with the
logarithm of serum KL-6 levels as the dependent variable.
To avoid high collinearity, the correlations between inde-
pendent variables were assessed by using Pearson’s corre-
lation coefficient. Correlation factors above 0.9 were
defined to have collinearity to exclude variables from the
multivariate analysis. The data were analyzed using SPSS
version 16.0.2 (SPSS Inc, Chicago, IL, USA).
Results
Patient characteristics at the time of diagnosis
Twenty-six patients with NSIP were eligible for this study.
Table 1 shows clinical and laboratory features of the
patients at the time of diagnosis. Thirteen patients had
a history of cigarette smoking. Interval from the onset of
subjective symptoms to the time of diagnosis ranged from
one month to 6 years.
Correlations between KL-6 and patient
characteristics
Serum KL-6 levels were not significantly different between
men and women, or between the smoking status groups.Table 1 Characteristics of study population.
Sex, men / women 13/13
Age, yr 61.0 (25e71)
Smoking History Never 12/Ever 14
Pack-year 4.5 (0e99)
Symptom Duration, mo 6.0 (1e72)
PaO2, torr 84.0 (65.8e104.6)
VC, %predicted 70.3 (41.7e116.7)
DLco, %predicted 46.9 (18.7e73.2)
BALF findings
Total Cell Counts, 105/mL 15.9 (0.5e54.1)
Macrophages, % 85.2 (30.0e98.6)
Lymphocytes, % 9.6 (0.4e66.4)
Neutrophils, % 2.2 (0e11.2)
Eosinophils, % 0.9 (0e27.8)
CD4/CD8 ratio 0.90 (0.16e7.65)
Data are shown as median (range), unless otherwise stated.
Definition of abbreviations: NeverZ patients who had not
smoked ever; EverZ patients who had any smoking history;
PaO2Z arterial oxygen tension; VCZ vital capacity; DLcoZ
carbon monoxide diffusing capacity of the lung; CD4/8
ratioZ ratio of helper cells/suppressor cells.There was no significant correlation between serum KL-6
levels and symptom duration (data not shown).
Comparison of serum markers
The serum levels of KL-6, LDH and CRP are shown in Fig. 1.
In order to reconfirm their diagnostic value in this pop-
ulation, we calculated the sensitivities of these serum
markers using the previously reported cut-off values. With
these cut-off levels, sensitivities were estimated to be 100%
(95% confidence interval [CI] 87%e100%) for KL-6, 46% (95%
CI 27%e67%) for LDH, and 54% (95% CI 33%e73%) for CRP.
Correlations between KL-6 and physiologic
parameters
Table 2 shows the correlations between KL-6 and other
parameters at baseline. Log KL-6 levels showed marginal
correlations with vital capacity % predicted and diffusing
capacity % predicted, respectively (Fig. 2). In contrast,
PaO2 and AaDO2 were not correlated with the serum levels
of KL-6 (Fig. 2). Neither BAL cell differentials nor the total
cell counts in BAL fluid showed correlation with the serum
KL-6. The serum levels of KL-6 showed a significant negative
correlation with baseline dyspnea index (Fig. 2).
High resolution CT findings of 26 patients
with NSIP
There was good interobserver agreement on the extent of
the parenchymal abnormalities (kappaZ 0.62e0.88). In
the 26 cases with f-NSIP, median areas of lung parenchyma
involving ground-glass opacity, consolidation, and abnormal
linear opacity were 17.9%, 4.4%, and 12.2%, respectively.
Abnormal linear opacity was always superimposed on areas
of ground-glass opacity; therefore, we defined an area of
pure ground-glass opacity (pure GGO) as an area of ground-
glass opacity without superimposed abnormal linear
opacity. In our patients pure GGO accounted for 5.5% of
lung parenchyma. The median number of lung segments
involved with traction bronchiectasis was 1.8 per patient.
Correlations between KL-6 and abnormal
findings on high resolution CT
As demonstrated in Table 3, serum levels of KL-6 also
showed significant correlations with the area of ground
glass opacity (rZ 0.574; pZ 0.0041), that of abnormal
linear opacity (rZ 0.586; pZ 0.0034) and the numbers of
lung segments involved with traction bronchiectasis seen on
high resolution CT (rZ 0.617; pZ 0.0020) (Fig. 3). Serum
levels of KL-6 were also correlated with the extent of total
opacity on high resolution CT (rZ 0.560; pZ 0.0051).
Serum levels of LDH and CRP did not show any significant
correlations with the areas of various abnormalities (data
not shown). Subsequently, a multivariate linear regression
analysis was performed. Among several types of abnor-
malities observed in HRCT only the number of segments
with traction bronchiectasis showed a significant and
dependent association with serum KL-6 level (Table 3).
Figure 1 Levels of KL-6, LDH and CRP in the serum from 26 patients with f-NSIP. The dashed horizontal lines represent the upper
limits of normal values.
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This study elucidated the relationship of serum KL-6 with
physiologic and radiologic parameters in f-NSIP. Several
studies10,11 have demonstrated the usefulness of KL-6 as
a marker for diagnosing IIPs. Many early investigations did
not evaluate the difference of pathologic subtypes, and to
our knowledge, no study has evaluated the relationships
between serum KL-6 and physiologic or radiologic parame-
ters on the basis of pathologic subtypes defined in the
consensus classification of IIPs.14
In our present study the serum KL-6 levels were elevated
above the reference range in all subjects. This result is in
agreement with previous study.15 LDH and CRP were
reported to be elevated in serum of the patients with
interstitial lung disease,16,17 although they are too
nonspecific to be used as a biomarker for IIPs. Comparing
these two parameters apparently showed the sensitivity of
serum KL-6 for f-NSIP.Table 2 Correlation analysis between serum KL-6 and clinical p
serum KL-6 Clinical Parameter Correlation with
serum KL-6
r p-value
CRP (mg/dL) 0.072 0.725
LDH (IU/mL) 0.313 0.119
PaO2 (torr) 0.147 0.474
AaDO2 (torr) 0.208 0.308
VC (%predicted) 0.381 0.055
FEV/FVC 0.264 0.192
DLco (%predicted) 0.375 0.059
Pearson’s linear regression models were employed for the valuables
models were employed for the valuables whose distribution was skew
Definition of abbreviations: BALFZ bronchoalveolar lavage fluid; TCC
CD4/8Z ratio of helper cells/suppressor cells; BDIZ baseline dyspneIn this study we elucidated the associations between the
serum KL-6 levels and the extent of abnormal parenchymal
opacities on high resolution CT. Our study demonstrated
that the serum levels of KL-6 were significantly correlated
with the extent of abnormal linear opacities and the
numbers of lung segments involved with traction bronchi-
ectasis. Moreover the multivariate analysis showed serum
KL-6 had a dependent association with the extent of trac-
tion bronchiectasis. Johkoh et al. reported that the extent
of reticular opacities and of traction bronchiectasis showed
the best correlation with the pathologic grade of fibrosis in
a series with 55 NSIP patients.18 Traction bronchiectasis has
been reported to correlate with pathologic findings of
fibrosis and poor prognosis in patients with IPF and hyper-
sensitivity pneumonitis.19,20 In this context we presumed
that elevated serum KL-6 levels reflect the severity of
fibrosis in f-NSIP. In contrast, a previous study in IPF
patients demonstrated that both surfactant protein (SP)-A
and SP-D, other biomarkers in pulmonary fibrosis, werearameters.
Clinical Parameter Correlation with
rho p-value
BDI* 0.520 0.006
BALF-TCC (104) 0.068 0.740
BALF-Neu (%) 0.040 0.844
BALF-Lym (%) 0.104 0.614
BALF-Eos (%) 0.334 0.095
BALF-AM (%) 0.146 0.478
BALF-CD4/8 0.127 0.537
with normal distribution. Spearman’s nonparametric regression
ed.
Z total cell counts; NeuZ neutrophils; LymZ lymphocytes;
a index. * Correlation is statistically significant.
Figure 2 Correlation between serum KL-6 levels and physiologic parameters. Scattered diagram showing the correlation between
serum KL-6 levels and vital capacity (% predicted) (on the left), serum KL-6 levels and carbon monoxide diffusing capacity
(%predicted) (on the middle), and serum KL-6 levels and severity of dyspnea (on the right). Severity of dyspnea was rated according
to baseline dyspnea index (BDI), its score ranging from 0 (most severe dyspnea) to 12 (least severe dyspnea).
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suppose KL-6 and surfactant proteins are both valuable
serum markers but reflect different pathophysiologic
processes.
Our data showed that the extent of ground-glass opacity
and the extent of total opacity were also associated with
serum KL-6 levels. However, the extents of these findings
were much influenced by the overlapped abnormal linear
opacity. The extent of pure ground-glass opacity, which is
defined as an area of ground-glass opacity without super-
imposed linear opacity, was not correlated with the serum
KL-6 levels in this study. In a comparative study between CT
scan and histopathology, pure GGO without overlapped
linear opacity or traction bronchiectasis was reported to be
a reliable indicator of inflammation in interstitial lung
diseases.22 We therefore speculated that serum KL-6 is not
a good inflammation marker.
In terms of physiologic parameters, marginally signifi-
cant correlations were observed between increased serum
KL-6 levels and impaired lung function such as vital
capacity and diffusing capacity. Previous larger case series
in sarcoidosis23 and systemic sclerosis5 demonstrated
significant correlations between KL-6 and diffusingTable 3 Correlation analysis between serum KL-6 and extent o
Univariate ana
rho
Total opacity, % 0.560
Ground-glass opacity, % 0.574
Air-space consolidation, % 0.227
Abnormal linear opacity, % 0.586
Honeycombing, % 0.160
Pure GGO, % 0.290
Segments with traction bronchiectasis, n 0.617
The multivariate analysis including all variables associated with KL-6
traction bronchiectasis was solely significantly correlated with serum
Definition of abbreviation: GGOZ ground glass opacity.
a Spearman’s rank correlation coefficient.
b Multivariate stepwise linear regression analysis.capacity. Relative small number of cases might make it
difficult to demonstrate the statistical significance.
In terms of BAL findings, there were no significant
correlations between the levels of KL-6 in serum and the
findings in BAL fluid, including cell differential % and CD4/8
ratio in lymphocyte subsets. Increased lymphocytes and
decreased ratio of CD4/CD8, each of which were reported
in early studies of NSIP,24 were not observed in our series.
A recent series with surgically proven cases showed the cell
differentials of BALF with f-NSIP did not differ from those
with UIP, and BAL findings had no prognostic value in
f-NSIP.25 We suspect that serum levels of KL-6 do not reflect
the inflammatory cells in the interstitium and are
compatible with the findings from CT analysis.
In the present study severity of dyspnea was assessed
with baseline dyspnea index, a well validated and reliable
multidimensional questionnaire for the measurement of
dyspnea. We demonstrated the correlations between serum
KL-6 levels and severity of dyspnea using this instrument.
To our knowledge, this is the first study showing the rela-
tionship between serum KL-6 and dyspnea in interstitial
lung disease. Recently Nishiyama et al. showed that BDI is
the best predictor of health-related quality of life amongf parenchymal abnormalities.
lysisa Mutlivariate analysisb
p-value b-coefficient (SE) p-value
0.005
0.004
0.256
0.003
0.422
0.148
0.002 0.043(0.012) 0.001
in univariate analysis showed that the number of segments with
KL-6 level.
Figure 3 Correlation between serum KL-6 levels and extents of various parenchymal abnormalities in high-resolution CT. Scatter
diagram showing the correlation between serum KL-6 levels and extent of pure ground glass opacity, serum KL-6 levels and extent
of consolidation, serum KL-6 levels and extent of abnormal linear opacity, serum KL-6 levels and number of segments with traction
bronchiectasis.
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exercise in IPF patients.26 Moreover severity of dyspnea at
the time of diagnosis is reported to be a predictor for the
survival of patients with IPF.27 Growing evidence suggests
the possibility of severity of dyspnea as an independent
surrogate marker for chronic fibrotic interstitial pneumo-
nias. Excellent correlation with dyspnea suggested a value
of serum KL-6 as a biomarker for f-NSIP.
Our study has several limitations. First, the study
involved a small number of patients from one center. In
addition, patients involved in the study consisted entirely
of Japanese. Larger studies are needed to confirm our
results and to evaluate whether this result can be adapted
to other ethnic groups or not. Second, we did not investi-
gate pathologic specimens. Whether serum KL-6 in f-NSIP is
correlated with fibrosis in pathologic specimens or not
should be evaluated in future study.
In conclusion, serum KL-6 levels showed positive
correlations with the extent of several patterns of opac-
ities in high-resolution CT and negative correlations with
baseline dyspnea index in univariate analysis. In multi-
variate analysis, the extent of traction bronchiectasis inhigh resolution CT showed a significant and dependent
association with serum KL-6 level. We speculate that
serum levels of KL-6 may be a marker for the fibrosing
process, rather than for the cellular inflammation in
f-NSIP. Further longitudinal studies including long-term
follow-up and therapeutic response in f-NSIP are war-
ranted, as well as an evaluation of the usefulness of serum
KL-6 in other subtypes of IIPs.
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